These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Dempke WC; Heinemann V Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922 [TBL] [Abstract][Full Text] [Related]
6. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653 [TBL] [Abstract][Full Text] [Related]
7. Molecular predictors of response to chemotherapy in colorectal cancer. Dienstmann R; Vilar E; Tabernero J Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555 [TBL] [Abstract][Full Text] [Related]
8. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Yarom N; Jonker DJ Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164 [TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Asghar U; Hawkes E; Cunningham D Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Banck MS; Grothey A Clin Cancer Res; 2009 Dec; 15(24):7492-7501. PubMed ID: 20008849 [TBL] [Abstract][Full Text] [Related]
11. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Bouché O; Beretta GD; Alfonso PG; Geissler M Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. Okada Y; Miyamoto H; Goji T; Takayama T Digestion; 2014; 89(1):18-23. PubMed ID: 24458108 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Modjtahedi H; Essapen S Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350 [TBL] [Abstract][Full Text] [Related]
14. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Berg M; Soreide K Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375 [TBL] [Abstract][Full Text] [Related]
15. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Troiani T; Zappavigna S; Martinelli E; Addeo SR; Stiuso P; Ciardiello F; Caraglia M Expert Opin Biol Ther; 2013 Feb; 13(2):241-55. PubMed ID: 23281932 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic mutations as predictive factors in colorectal cancer. Lièvre A; Blons H; Laurent-Puig P Oncogene; 2010 May; 29(21):3033-43. PubMed ID: 20383189 [TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Heinemann V; Douillard JY; Ducreux M; Peeters M Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249 [TBL] [Abstract][Full Text] [Related]
18. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. Osera S; Yoshino T Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345 [TBL] [Abstract][Full Text] [Related]
19. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Yang J; Li S; Wang B; Wu Y; Chen Z; Lv M; Lin Y; Yang J Tumour Biol; 2016 Sep; 37(9):11645-11655. PubMed ID: 27422777 [TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? Valentini AM; Pirrelli M; Caruso ML Curr Opin Mol Ther; 2008 Apr; 10(2):124-31. PubMed ID: 18386224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]